Thromboembolic diseases are common. Heparins and the vitamin K antagonists have been
the mainstay of therapy for> 60 years, but both classes of agents have limitations. The “ideal” …

Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism,
is a cause of significant mortality and morbidity. For several decades, anticoagulant options …

Dabigatran, rivaroxaban, and apixaban are novel oral anticoagulants that offer major
advantages over existing agents. The onset of the anticoagulant effect of these agents is …

Background Novel oral anticoagulants are approved in several indications: rivaroxaban,
apixaban, and dabigatran for the prevention of venous thromboembolism after elective hip …

Thromboembolic disorders are among the major causes of morbidity and mortality, and
anticoagulation remains the cornerstone of prevention and treatment of these disorders …

The quest for an ideal anticoagulant is ongoing. Oral agents that do not require blood level
monitoring are presently undergoing taut scrutiny for efficacies and potential side effects …

The quest for an ideal anticoagulant is ongoing. Oral agents that do not require blood level
monitoring are presently undergoing taut scrutiny for efficacies and potential side effects …

Arterial and venous thromboembolic diseases are a clinical and economic burden
worldwide. In addition to traditional agents such as vitamin K antagonists and heparins …

While parenteral anticoagulants such as unfractionated and low molecular weight heparins
and the oral vitamin K antagonists are effective for the prevention and treatment of …

Vitamin K antagonists, such as warfarin, have been the mainstay of oral anticoagulation for
many decades. Although effective, warfarin has numerous limitations, including a variable …